Elevated LLT1 expression on T cells in high-risk ALL patients may contribute to the inhibitory LLT1–NKRP1A interaction with NK cells, potentially enabling leukemic cells to evade NK cell-mediated cytotoxicity. This evidence concerns the gene CLEC2D and acute lymphoblastic leukemia.